恶性肿瘤患者外周血T淋巴细胞CD25的测定与临床检验学研究  

Measurement and clinical test studies of T lymphocyte CD25 in peripheral blood for patients with malignant tumor

作　　者：赵衍江[1] 刘晓华[1] 喻茂杰[1] 金哲[1] 鲍连勇[1] 

机构地区：[1]中国医科大学辽阳中心医院检验科,辽宁辽阳111000

出　　处：《中国当代医药》2012年第32期99-100,共2页China Modern Medicine

摘　　要：目的探讨恶性肿瘤患者T淋巴细胞CD25+水平的临床意义。方法用流式细胞仪检测70名正常人和274例恶性肿瘤患者外周血CD4+CD25+和CD8+CD25+水平。结果恶性肿瘤患者外周血CD4+CD25+水平比正常人高,差异有统计学意义(P<0.05);恶性肿瘤患者外周血CD8+CD25+水平与正常人比较,差异无统计学意义(P>0.05)。其中,食管癌、肝癌和肺癌的CD4+CD25+水平与正常人比较,差异有统计学意义(P<0.05);肠癌、胃癌和鼻咽癌的CD4+CD25+水平与正常人比较,差异无统计学意义(P>0.05)。结论恶性肿瘤患者外周血CD4+CD25水平的增高可作为恶性肿瘤免疫诊断的参考指标。Objective To explore the clinical significance of the level of T lymphocyte CD25＋ for patients with malignant tumor. Methods The percentage level of CD4＋CD25＋ and CD8＋CD25＋ in peripheral blood in 70 cases of normal people and 274 patients with malignant tumor were tested by flow cytometry instrument. Results The levels of CD4＋CD25＋ in peripheral blood of patients with malignant tumor were higher than that of the normal people, there was significant difference （P 0.05）; the levels of CD8＋CD25＋ in peripheral blood of patients with malignant tumor had no significant difference compared with the normal people （P 0.05）; the levels of CD4＋CD25＋ in the esophageal cancer, liver cancer and lung cancer had significant difference compared with normal people （P 0.05）; the levels of CD4＋CD25＋ in the colorectal cancer, stomach cancer and of nasopharyngeal carcinoma had no significant difference compared with the normal people （P 0.05）. Conclusion The increase of the levels of CD4＋CD25＋ in peripheral blood for patients with malignant tumor can be used as the reference index for the diagnosis of malignant tumor immune.

关 键 词：恶性肿瘤 CD4+CD25+ CD8+CD25+ 流式细胞术 

分 类 号：R446.6[医药卫生—诊断学]